Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
The product is expected to be launched by Q4 FY23.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Subscribe To Our Newsletter & Stay Updated
